T-cell prolymphocytic leukemia screening: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{T-cell prolymphocytic leukemia}} | |||
{{CMG}}; {{AE}}{{Qurrat}}, {{MV}} | |||
{{T-cell-prolymphocytic leukemia}} | {{T-cell-prolymphocytic leukemia}} | ||
Revision as of 22:10, 25 March 2019
|
T-cell prolymphocytic leukemia Microchapters |
|
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
T-cell prolymphocytic leukemia screening On the Web |
|
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia screening |
|
Risk calculators and risk factors for T-cell prolymphocytic leukemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3]
|
T-cell prolymphocytic leukemia Microchapters |
|
Differentiating T-cell Prolymphocytic Leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
T-cell prolymphocytic leukemia screening On the Web |
|
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia screening |
|
Directions to Hospitals Treating T-cell prolymphocytic leukemia |
|
Risk calculators and risk factors for T-cell prolymphocytic leukemia screening |